Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cubist: Antibiotic validation

Companies could produce new antibiotics faster and more reliably if they had better tools to identify target bacterial proteins that are essential to virulence in mammals. Cubist Pharmaceuticals Inc. believes that its peptide selection and expression approach will be useful for pathogen target validation and discovery of small molecule antibiotics.

CBST researchers last week published, in the Proceedings of the National Academy of Sciences, the company's Validation In Vivo of Targets and Assays for Antiinfectives (VITA) technology. VITA uses peptides selected in vitro that bind to potential pathogen targets, combined with inducible expression of the peptides in a virulent bacterial strain, to validate targets derived from genomic studies.

If in vivo expression of a peptide in a bacterial strain protects mice from what would

Read the full 1222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE